Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | KLF10 | Q13118 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL341802 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL34268 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2209541 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2206798 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL649168 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL122111 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29528186 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185801-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-11130734-B2 | Amino alcohol-boron-binol complex and method for preparing optically active amino alcohol derivative by using same | MOLECULES & MATERIALS CO., LTD. (KR) | 2021-09-28 | — | — | US | disclosed |
| US-20210206719-A1 | AMINO ALCOHOL-BORON-BINOL COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE BY USING SAME | MOLECULES & MATERIALS CO., LTD. (KR) | 2021-07-08 | — | — | US | disclosed |
| US-10954250-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-03-23 | — | — | US | disclosed |
| WO-2021046438-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9604906-B2 | Process for the preparation of 3-aryloxy-3-phenylpropylamine and salt thereof | ZCL CHEMICALS LIMITED (IN) | 2017-03-28 | — | — | US | disclosed |
| US-9604906-B2 | Process for the preparation of 3-aryloxy-3-phenylpropylamine and salt thereof | ZCL CHEMICALS LIMITED (IN) | 2017-03-28 | — | — | US | disclosed |
| EP-2838510-B1 | ATOMOXETINE SOLUTION | LILLY CO ELI (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2007030587-A1 | PROCESSES FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-03-15 | — | — | WO | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007010082-A1 | PROCESS FOR PREPARING A 3-ARYLOXY-3-ARYLPROPYLAMINE | FERMION OY (FI) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009405-A1 | A METHOD FOR THE PREPARATION OF (R)-N-METHYL-3-(2-METHYLPHENOXY)-3-PHENYLPROPYLAMINE HYDROCHLORIDE (ATOMOXETINE) | ZENTIVA, A.S. (CZ) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006108120-A1 | STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITY | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006037055-A1 | SYNTHESIS OF ATOMOXETINE HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006020348-A2 | POLYMORPHS OF ATOMOXETINE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006004923-A2 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004976-A2 | PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004977-A2 | PROCESS FOR THE OPTICAL RESOLUTION AND RECYCLING OF TOMOXETINE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130734-B2 | Amino alcohol-boron-binol complex and method for preparing optically active amino alcohol derivative by using same | BCAT1, BCAT2, HBS1L | SLC6A2 1343/4885SLC6A4 2273/4885CYP1A2 1742/4885 |
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | KLF10, KLF5, ICOS | SLC6A2 4752/4885SLC6A4 4644/4885CYP1A2 4846/4885 |
| US-10954250-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | SLC6A2 8/4885SLC6A4 106/4885CYP1A2 23/4885 |
| US-20220185801-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | KLF10, KLF5, ICOS | SLC6A2 4752/4885SLC6A4 4644/4885CYP1A2 4846/4885 |
| US-20210206719-A1 | AMINO ALCOHOL-BORON-BINOL COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE BY USING SAME | BCAT1, BCAT2, HBS1L | SLC6A2 1133/4885SLC6A4 1828/4885CYP1A2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.